-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| Sector | Healthcare |
| Industry | Biotechnology |
| ISIN | IE000LK2BOB4 |
| Market Cap | 46M |
|---|---|
| PE Ratio | None |
| Target Price | 5 |
| Beta | nan |
| Dividend Yield | None |
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MURA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025